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A B S T R A C T
Purpose
Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are
poorly understood.
Materials and Methods
Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et
Recherche en Cance´rologie Digestive) database were pooled. Multivariable logistic regression
models for 30-, 60-, and 90-day mortality were constructed, including clinically and statistically
signiﬁcant patient and disease factors and interaction terms. A calculator (nomogram) for 90-day
mortality was developed and validated internally using bootstrapping methods and externally using
a 10% random holdout sample from each trial. The impact of early progression on the likelihood of
survival to 90 days was examined with time-dependent Cox proportional hazards models.
Results
Mortality rates were 1.4% at 30 days, 3.4% at 60 days, and 5.5% at 90 days. Among baseline
factors, advanced age, lower body mass index, poorer performance status, increased number of
metastatic sites, BRAF mutant status, and several laboratory parameters were associated with
increased likelihood of early mortality. A multivariable model for 90-day mortality showed strong
internal discrimination (C-index, 0.77) and good calibration across risk groups as well as accurate
predictions in the external validation set, both overall and within patient subgroups.
Conclusion
A validated clinical nomogram has been developed to quantify the risk of early death for indi-
vidual patients during initial treatment of metastatic colorectal cancer. This tool may be used for
patient eligibility assessment or risk stratiﬁcation in future clinical trials and to identify patients
requiring more or less aggressive therapy and additional supportive measures during and after
treatment.
J Clin Oncol 35:1929-1937. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Randomized controlled clinical trials play a piv-
otal role of establishing new or improved cancer
treatments within particular tumor types or pa-
tient populations, yet the rate of clinical trial
participation among patients with cancer re-
mains , 5%.1 It would be valuable to be able to
identify those patients at an increased risk of
severe toxicity or early mortality, for whom re-
ceipt of treatment may be associated with greater
risk than beneﬁt and whose inclusion may ob-
scure the assessment of treatment effect because
they do not meet evaluation criteria for critical
end points. For this reason, most cancer clinical
trials limit enrollment to those patients who are
expected to live at least 3 to 6 months beyond
treatment initiation, with exact speciﬁcations
depending on the speciﬁc disease under study.2
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Assessment of patient prognosis is inherently subjective, however,
and often requires the treating physician to consider an array of
patient and disease factors that may be clinically challenging to
synthesize.
Within metastatic colorectal cancer (mCRC), the relative
contribution of commonly measured patient and disease char-
acteristics to a given individual’s likelihood of early mortality, and
whether or how these features may interact, remains poorly un-
derstood. McPhail et al3 conducted a population-based analysis of
early mortality (deﬁned by the authors as death within 1 year of
diagnosis) among all patients diagnosed with breast, colorectal,
lung, prostate, or ovarian cancers in England in 2012 and found
age, stage of disease at diagnosis, income, and geographic location
to be independent predictors of mortality. A similar analysis
limited to patients diagnosed with colorectal cancer in England
between 2006 and 2008 found that approximately 33% of patients
diagnosed with colon cancer and 25% of patients with rectal cancer
die within 1 year of diagnosis, with advanced age, later stage at
diagnosis, deprivation, and emergency presentation associated
Table 1. Demographics and Disease Characteristics of Patients Used for the
Early Mortality Analyses
Variable No. Average %
Age, years
Mean (SD) 61 (11)
Median (IQR) 62 (55-69)
Missing 7 0
Sex
Male 13,902 62
Female 8,622 38
Missing 18 0
Performance status
0 11,966 53
1 9,483 42
2+ 974 4
Missing 231 1
BMI
Mean (SD) 26 (5)
Median (IQR) 25 (23-29)
Missing 1,533 7
Tumor location
Colon 11,829 69
Rectum 5,035 29
Both 282 2
Missing 5,508 24
No. organs with metastases
0-1 8,220 44
2 6,561 35
3 2,834 15
4+ 900 5
Missing 4,139 18
Liver involvement
Yes 14,441 78
No 4,100 22
Missing 4,113 18
Lung involvement
Yes 6,657 37
No 11,260 63
Missing 4,737 21
Peritoneal involvement
Yes 1,642 16
No 8,674 84
Missing 12,338 54
LN involvement
Yes 6,157 39
No 9,660 61
Missing 6,837 30
Prior chemotherapy
Yes 4,313 21
No 16,153 79
Missing 2,188 10
KRAS
Mutant 3,025 38
Wild type 4,885 62
Missing 14,744 65
BRAF
Mutant 387 8
Wild type 4,423 92
Missing 17,844 79
WBC count, 3 109/L
Mean (SD) 8.4 (3.4)
Median (IQR) 7.8 (6.3-9.7)
Missing 4,436 20
ANC, 3 109/L
Mean (SD) 5.7 (2.7)
Median (IQR) 5.1 (3.9-6.8)
Missing 6,497 29
(continued in next column)
Table 1. Demographics and Disease Characteristics of Patients Used for the
Early Mortality Analyses (continued)
Variable No. Average %
dNLR
Mean (SD) 2.4 (1.4)
Median (IQR) 2.1 (1.5-2.8)
Missing 8,532 38
Platelets, 3 109/L
Mean (SD) 335 (128)
Median (IQR) 310 (245-398)
Missing 1,887 8
Hemoglobin, g/dL
Mean (SD) 12.4 (1.7)
Median (IQR) 12.4 (11.2-13.6)
Missing 7,691 34
Bilirubin, mg/dL
Mean (SD) 0.63 (0.94)
Median (IQR) 0.50 (0.34-0.69)
Missing 3,010 13
Treatment class
Targeted 9,710 43
Nontargeted 12,944 57
Missing 0 0
Targeted Rx type
Anti-ANG 6,177 64
Anti-EGFR 2,646 27
Both 887 9
Not applicable 12,944 49
Death by 30 days
Yes 298 1.3
No 22,356 98.7
Missing 0 0
Death by 60 days
Yes 761 3.4
No 21,823 96.6
Missing 70 0.3
Death by 90 days
Yes 1,234 5.5
No 21,290 94.5
Missing 130 0.6
Abbreviations: ANC, absolute neutrophil count; ANG, angiogenic; BMI, body
mass index; dNLR, derived neutrophil-to-lymphocyte ratio; EGFR, epidermal
growth factor receptor; IQR, interquartile range; LN, lymph node; Rx, treatment;
SD, standard deviation.
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with an increased likelihood of early death. However, relative rather
than absolute risks of early mortality by initial stage of disease were
presented by the authors, such that the empiric death rate among
patients with metastatic disease alone could not be assessed.4
Furthermore, mortality by time points earlier than 1 year was
not reported. Lieu et al5 and Renfro et al6 reported that extreme
(young or old) age and low body mass index (BMI), respectively,
were associated with poorer survival in an ARCAD (Aide
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Fig 1. Nonlinear continuous univariable ef-
fects of (A) age, (B) body mass index (BMI),
(C) bilirubin, (D) hemoglobin, (E) platelets, (F)
WBC count, (G) absolute neutrophil count
(ANC), and (H) derived neutrophil-to-lymphocyte
ratio (dNLR) on early mortality at 30, 60, and 90
days. Shaded gray regions are 95% conﬁdence
bands.
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et Recherche en Cance´rologie Digestive) analysis of patients en-
rolled in clinical trials of ﬁrst-line treatment of mCRC, although
early mortality was not a focus of these analyses. Shibutani et al7
suggested that pretreatment albumin to globulin ratio may predict
survival and response to chemotherapy in unresectable mCRC, but
likewise did not examine early mortality. Ko¨hne et al8 and Chi-
baudel9 developed risk scoring systems to predict overall survival in
patients receiving front-line treatment of mCRC; however, again,
neither tool speciﬁcally examined early mortality and each was
based on far fewer patients than are presently available in the
ARCAD database.
In addition to limited knowledge of prognostic factors as-
sociated with early mortality in mCRC, to our knowledge, clinical
tools for predicting the likelihood of early mortality for a given
patient do not currently exist for this patient population, although
one such tool was recently developed for early-stage colon cancer.10
Because overall survival can be highly variable inmetastatic disease,
the ability to objectively determine information about an indi-
vidual patient’s disease status and clinical characteristics and use
these to construct an individualized prediction of the likelihood of
90-day survival could serve two key purposes: identiﬁcation of
patients requiring aggressive supportive care during initial therapy
and improved patient selection processes for ongoing and future
clinical trials.
To improve our collective understanding of prognostic factors
related to early mortality in mCRC, we pooled individual patient
data from . 20,000 individuals enrolled in 28 randomized front-
line clinical trials and identiﬁed factors (directly or differentially)
associated with early mortality. We then used these factors to
develop a tool for clinical assessment of patients being considered
for participation in ﬁrst-line trials for mCRC.
MATERIALS AND METHODS
Description and Purpose of the ARCAD Database
The ARCAD database contains individual data on . 20,000 patients
enrolled in 28 randomized front-line trials in mCRC since 1997 (Appendix
Table A1, online only). The ARCAD collaborative group was originally
established to study end points such as progression-free survival as
candidate surrogates for overall survival, and since then it has also pro-
duced a number of major analyses to improve understanding of this
disease.5,6,11
Statistical Methods
Descriptive statistics for patient, disease, and treatment character-
istics as well as mortality rates at each time point of interest (30, 60,
90 days) were computed, and rates of missing data reported. For prog-
nostic modeling, patient factors collected at the time of randomization
were evaluated for possible associations with early mortality including age;
sex; performance status (PS; 0, 1, 2+); BMI; BRAF or KRAS status (mutant
[MT] v wild type [WT]); number of metastatic sites, counted as number of
affected organs (0 or 1, 2, 3, 4+); presence versus absence of liver, lung,
peritoneal, and lymph node metastases; prior chemotherapy (yes, no);
baseline bilirubin, hemoglobin, platelets, WBC count, absolute neutrophil
count (ANC), derived neutrophil to lymphocyte ratio (dNLR);12,13
treatment class (targeted v nontargeted); and targeted treatment type
(antiangiogenic v anti–epidermal growth factor receptor). Missing baseline
data were accounted for via multiple imputation; speciﬁcally, bootstrapped
regression with predictive mean matching was used to maintain a level of
variability in the imputed data similar to what exists in the available
data.14,15 Outcome data (mortality and progression times) were not im-
puted. Some variables of interest, such as side of primary tumor (right v
left) were excluded from consideration in this analysis because values were
missing for . 50% of patients, with the most common reason for un-
available data being that these items were not collected by some trials.
To quantify the impact of baseline prognostic factors on the likeli-
hood of early mortality, logistic regression models with single predictor
variables of interest were ﬁt to identify signiﬁcant predictors of mortality at
each time point, where signiﬁcance required both P , .05 and clinically
meaningful effects (odds ratios [ORs]). In models containing continuous
variables, restricted cubic splines14,15 were used to test for possible
nonlinearity of the effects on the log odds scale. When signiﬁcant (P, .05)
nonlinearity (such as U-shaped risk of early mortality) as a function of
a given candidate variable was found, the effect curve was plotted on the
probability scale with 95% conﬁdence bands for visual inspection, and
spline modeling was subsequently carried forward inmultivariable models;
otherwise, standard linear modeling was subsequently used. Two-way
interactions were tested between signiﬁcant independent variables,
where P , .01 for both the interaction effect and clinically differentiable
effects (ORs or curves) across factor levels indicated signiﬁcance. Statistically
and clinically signiﬁcant variables were then carried forward tomultivariable
logistic regression models for each time point; variables no longer con-
tributing either statistically or clinically on statistical adjustment were then
excluded, resulting in ﬁnal multivariable models for each time point.
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Fig 1. (Continued).
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Finally, a nomogram (calculator) was developed from the ﬁnal
multivariable model for mortality within 90 days of protocol enrollment.
As measures of internal validation, the concordance index (C-index;
equivalent to the area under the receiver operating characteristic curve)
and a bootstrapping-based calibration plot of actual versus predicted
outcomes were reported, where the latter contained a nonparametrically
smoothed curve representing the functional relationship between actual
versus predicted outcomes over risk groups.14,15 External validation of the
nomogramwas performed using a 10% random holdout sample from each
trial; because of the rarity of early mortality events within any individual
trial, it was deemed not feasible to conduct external validation using any
single separate trial. Disease progression (as a time-varying variable) was
excluded from consideration in ﬁnal models, because progression status is
generally unknown at the time when the tool being developed here is
intended for use. Analyses were performed using the R project for sta-
tistical computing (http://www.R-project.org).
RESULTS
Descriptive Statistics
A total of 22,654 patients enrolled in 28 ARCAD trials were
analyzed (Appendix Table A1). Across these trials, the median
length of follow-up among living patients is 19 months. Baseline
patient demographics and disease characteristics are summa-
rized in Table 1. The mean age was 61 years, 62% of patients
were male, 53% had an Eastern Cooperative Oncology Group
performance status of 0, 69% had primary tumors in the colon
only, and 21% had received prior chemotherapy. Early mortality
rates were as follows: 1.4% at 30 days, 3.4% at 60 days, and 5.5%
at 90 days.
Table 2. Empirical (unadjusted) Probabilities of Early Mortality and Multivariable (adjusted) ORs, 95% CIs, and P Values for Early Mortality at Each Time Point, on the
Basis of the Construction Data Set (N = 22,654)
Variable
30 Days 60 Days 90 Days
Rate OR (95% CI) P Rate OR (95% CI) P Rate OR (95% CI) P
Age, years , .001 , .001 , .001
50 0.008 – 0.023 – 0.041 –
60 0.010 1.54 (1.13 to 2.10) 0.026 1.22 (0.98 to 1.51) 0.045 1.19 (0.99 to 1.42)
70 0.017 2.34 (1.72 to 3.19) 0.041 1.87 (1.52 to 2.28) 0.065 1.68 (1.42 to 2.00)
80 0.034 3.55 (2.50 to 5.04) 0.074 3.19 (2.46 to 4.13) 0.106 2.59 (2.08 to 3.22)
BMI , .001 , .001 , .001
15 0.034 2.91 (1.72 to 4.90) 0.085 2.94 (2.06 to 4.19) 0.107 2.70 (2.01 to 3.60)
20 0.020 1.80 (1.28 to 2.52) 0.050 1.88 (1.49 to 2.37) 0.080 1.80 (1.49 to 2.19)
30 0.011 – 0.025 1.08 (0.87 to 1.34) 0.042 1.10 (0.91 to 1.31)
40 0.009 1.02 (0.56 to 1.82) 0.020 – 0.035 –
PS , .001 , .001 , .001
0 0.008 – 0.017 – 0.028 –
1 0.017 1.56 (1.18 to 2.04) 0.044 1.92 (1.60 to 2.31) 0.074 1.96 (1.69 to 2.27)
2+ 0.050 3.02 (2.05 to 4.47) 0.134 4.37 (3.37 to 5.67) 0.201 4.38 (3.52 to 5.44)
BRAF , .001 , .001 , .001
WT 0.011 – 0.028 – 0.046 –
MT 0.043 3.78 (2.88 to 4.98) 0.090 3.18 (2.62 to 3.86) 0.148 3.52 (3.01 to 4.12)
No. metastasis sites , .001 , .001 , .001
0-1 0.010 – 0.025 – 0.043 –
2 0.015 1.49 (1.11 to 1.98) 0.034 1.26 (1.04 to 1.52) 0.054 1.22 (1.05 to 1.41)
3 0.020 1.92 (1.37 to 2.68) 0.048 1.71 (1.37 to 2.13) 0.076 1.66 (1.39 to 1.98)
4+ 0.026 2.24 (1.41 to 3.56) 0.062 1.97 (1.45 to 2.68) 0.106 2.13 (1.67 to 2.71)
Bili, mg/dL , .001 , .001 , .001
1 0.017 – 0.040 – 0.066 –
5 0.024 1.47 (0.94 to 2.29) 0.050 1.26 (0.90 to 1.77) 0.081 1.24 (0.94 to 1.65)
10 0.035 2.38 (1.09 to 5.18) 0.067 1.69 (0.91 to 3.12) 0.105 1.63 (0.97 to 2.72)
15 0.051 3.85 (1.19 to 12.0) 0.089 2.26 (0.89 to 5.60) 0.135 2.13 (0.98 to 4.52)
WBC count, 3 109/L , .001 , .001 , .001
5 0.005 – 0.009 – 0.021 –
10 0.019 2.67 (1.93 to 3.70) 0.049 2.31 (1.83 to 2.91) 0.075 1.74 (1.43 to 2.11)
15 0.025 3.39 (2.44 to 4.71) 0.065 2.71 (2.11 to 3.49) 0.101 2.01 (1.63 to 2.49)
20 0.030 4.19 (2.95 to 5.95) 0.082 3.11 (2.32 to 4.15) 0.132 2.30 (1.79 to 2.94)
dNLR .0046
1 0.008 –
5 0.020 1.74 (1.25 to 2.41)
10 0.026 1.88 (1.23 to 2.88)
15 0.036 2.04 (1.09 to 3.80)
ANC, 3 109/L , .001 , .001
1 0.004 – 0.012 –
5 0.026 1.43 (1.16 to 1.78) 0.045 1.42 (1.19 to 1.70)
10 0.069 2.29 (1.80 to 2.92) 0.106 2.24 (1.82 to 2.75)
15 0.130 3.64 (2.59 to 5.11) 0.199 3.51 (2.62 to 4.69)
NOTE. Age, BMI, and laboratory values are modeled as continuous and nonlinear on the log odds scale. The dash (–) indicates the reference group with lowest risk.
Variables not contributing signiﬁcantly to at least one time point’s model after adjustment are excluded.
Abbreviations: ANC, absolute neutrophil count; Bili, bilirubin; BMI, body mass index; dNLR, derived neutrophil-to-lymphocyte ratio; MT, mutant; OR, odds ratio;
PS, performance status; WT, wild type.
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Univariable and Pairwise Interaction Models for Early
Mortality
In the construction data set (N = 20,397), age was associated
with early mortality at every time point (P , .001), and, in each
case, the risk of early death was found to increase with age in
a nonlinear fashion on the log-odds scale (Fig 1A). BMI was also
signiﬁcantly associated with early mortality at each time point
(P, .001), with the highest risk of death observed in the cohort with
the lowest BMI and decreasing risk according to a nonlinear function
for patients with higher BMI (Fig 1B). Another strong predictor of
early mortality was PS, where worse PS was highly associated with
early mortality at all time points (P, .001 for 30, 60, and 90 days;
90-day PS1/PS0 OR, 2.71; PS2+/PS0 OR, 8.62). BRAFMT (vWT)
status was associated with increased likelihood of early mortality at
each time point (P, .001 for 30, 60, and 90 days; 90-day MT/WT
OR, 3.62), whereas prior receipt of chemotherapy for any reason
was associated with decreased likelihood of early mortality at each
time point (30-day OR, 0.66; P = .01; 60-day OR, 0.67; P , .001;
90-day OR, 0.76; P , .001). Having more metastatic sites was
signiﬁcantly associated with increased likelihood of early mortality
at all time points (P , .001 for 30, 60, and 90 days, with 90-day
ORs of 1.28, 1.83, and 2.65 for 2, 3, and 4 v 0 or 1 metastatic site,
respectively). At all time points, presence of peritoneal metastases
was further associated with an increased likelihood of early
mortality (30-day OR, 1.75; P , .001; 60-day OR, 1.59; P , .001;
90-day OR, 1.64; P , .001), and metastasis to distant lymph
nodes was also associated with early mortality at 90 days (90-day
OR, 1.28; P , .001). All baseline laboratory values that were
considered (bilirubin, hemoglobin, platelets, WBC count, ANC,
and dNLR) were associated with early mortality at all time points
(P values ranging from , .001 to .0041), some via nonlinear
relationships, as shown in Figures 1C-1H. Patient sex, KRAS
status, tumor location (colon v rectum), and presence of liver or
lung metastases were not signiﬁcantly associated with early
mortality at any time point. Among trials with concurrent
randomization, class of therapy (targeted v nontargeted) was not
associated with early mortality. No pairwise interactions showed
both statistical and clinical signiﬁcance on visual inspection at any
time point.
Multivariable Analyses for Early Mortality
Final multivariable models retaining statistically and clin-
ically relevant terms after adjustment are shown in Table 2. In the
ﬁnal multivariable model for mortality by 30 days, increased age
(P , .001), decreased BMI (P , .001), worse PS (P , .001),
BRAF MT status (P , .001), increased number of metastatic
sites (P , .001), increased bilirubin (P , .001), increased WBC
count (P , .001), and increased derived neutrophil-to-lymphocyte
ratio (dNLR) (P = .0046) were associated with an increased like-
lihood of early death. The ﬁnalmultivariablemodels formortality by
60 and 90 days were similar, with increased ANC rather than in-
creased dNLR showing a signiﬁcant association with early mortality
(P , .001 in both models).
Nomogram for 90-Day Mortality: Internal Validation
The ﬁnal multivariable model for mortality by 90 days showed
strong internal validity, with a discrimination C-index of 0.772
indicating a 72.2% correct model identiﬁcation of the higher-risk
patient across all possible pairs of patients. Furthermore, the ﬁnal
model for mortality by 90 days demonstrated good internal cal-
ibration of observed versus predicted outcomes across a spectrum
of risk groups, as shown in Figure 2. A nomogram represen-
tation of the model is provided in Figure 3, where for a speciﬁc
patient, the predicted probability of early mortality by 90 days
can be computed (see Appendix, online only, for nomogram
instructions).
Nomogram for 90-Day Mortality: External Validation
External validation results for the ﬁnal 90-day model are
shown in Table 3. A total of 2,230 patients with known survival
status at 90 days composed the validation cohort, representing
a 10% holdout sample from each trial. Of these patients, 127
(5.7%; 95% CI, 4.8% to 6.8%) died by 90 days, with the average
model-predicted rate of 5.0% falling within the 95% CI for the
actual rate. In addition, within each patient subgroup (deﬁned by
levels of each variable in the ﬁnal model), the average predicted rate
fell within the corresponding 95% interval for the actual rate with
just one exception: the subgroup of patients with four or more
metastatic sites had a lower mortality rate (4.0%: 95% CI, 2.3% to
6.8%) than the predicted rate (8.7%) for that group.
The ability of this model to distinguish between low-risk and
high-risk patients can be demonstrated by considering two hy-
pothetical individuals who might be encountered in practice:
patient A is 61 years old with BMI of 20, PS of 0, BRAFWTstatus,
one metastatic site, bilirubin of 0.5 mg/dL, WBC count of 8.0 3
109/L, and ANC of 6.03 109; patient B is 79 years old with BMI of
30, PS of 1, BRAF MT status, three metastatic sites, bilirubin of 1.9
mg/dL, WBC count of 12.0 3 109, and ANC of 9.0 3 109. Our
model predicts that patient A has a 2.5% chance of early death by
90 days (95% CI, 2.0% to 3.0%), and patient B has a 42% chance of
early death (95%CI, 36% to 48%). That is, the risk of early mortality
for patient B is predicted to be 16.8 times the risk for patient A.
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Fig 2. Calibration of the nomogram for 90-day mortality.
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DISCUSSION
In this pooled analysis of . 22,000 patients from 28 randomized
clinical trials of front-line treatment in mCRC, 5.5% of patients
had died within 90 days after being randomly assigned. When
factors contained in the ARCAD database were investigated, we
found that increased age, decreased BMI, worsened PS, a greater
number of metastatic sites, BRAF MT status, and elevated labo-
ratory markers collectively representing an inﬂammatory response
were associated with an increased likelihood of death in the ﬁrst
90 days, whereas KRAS status, patient sex, individual sites of
metastases, location of primary tumor (colon v rectum), and prior
chemotherapy use did not seem to play an early prognostic role.
To support identiﬁcation of patients with a dramatically in-
creased likelihood of early mortality, we constructed and validated
a nomogram to aid clinical prognostication and facilitate in-
dividualized evaluation of patients with advanced disease. We
anticipate that this calculator will be especially useful in conﬁrming
patient eligibility for future clinical trials and limiting enrollment
to patients whose likelihood of survival beyond 90 days is rea-
sonably high, such that the effect of experimental treatments on
clinical outcomes may be evaluated more clearly and with less
attrition due to early deaths. In addition, patients identiﬁed as at
high risk of short-term mortality could be managed with more- or
less-intensive therapy, depending on patient preferences and joint
patient-physician decision making, as well as offered enhanced
supportive care if they are to be treated outside the auspices of
a clinical trial. A tool that allows clinicians to stratify patients
according to risk of early death more effectively could also aid in
developing trials focusing on supportive care needs in the pop-
ulation of patients with poor prognosis, potentially affecting both
quantity and quality of life. Signiﬁcantly, we may then start to
identify therapeutic strategies that may bemore harmful to patients
and thus tailor the results of trials into clinical practice in a more
individualized manner.
There are some limitations to our work. First, among the trials
considered, we were unable to reliably distinguish between early
deaths due to documented progression versus deaths potentially
related to treatment toxicity, without making broad assumptions
that may have been misleading. For this reason, throughout, we
focus on purely prognostic analyses of factors known at baseline
(time of randomization). Second, although location of primary
tumor (right v left) has recently been identiﬁed as a prognostic
(and perhaps predictive) factor in the metastatic disease
setting,16,17 we were unable to assess this factor in the present
analysis of early mortality, because tumor sidedness was only noted
in a small minority of trials, precluding imputation of missing data.
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Similarly, laboratory markers including serum lactate de-
hydrogenase, carcinoembryonic antigen, and C-reactive protein
were not considered, because sparse data collection and non-
standardized assays across trials made their inclusion infeasible.
We also note that our ﬁndings are only applicable to patients
with advanced colorectal cancer about to initiate front-line
therapy and, more speciﬁcally, those who might also meet the
eligibility criteria for participation in our clinical trials. To the
degree that a patient encountered in practice has worse per-
formance status or additional comorbidities than a typical trial-
eligible patient, the probabilities of early mortality presented
here may be viewed as best-case scenario at the treating phy-
sician’s discretion. Despite these theoretical limitations, the
present validated tool, on the basis of patient-level data from
28 major randomized clinical trials, will prove useful for trial
eligibility screening and patient stratiﬁcation as well as iden-
tiﬁcation of patients in clinical practice who may beneﬁt from
more or less aggressive treatment.
In summary, the rate of early mortality by 90 days across 28
ﬁrst-line trials conducted in patients with mCRC was 5.5%, with
several patient and disease factors showing strong associations
with increased or decreased likelihood of this outcome. A vali-
dated clinical nomogram taking these characteristics into account
may be potentially useful for quantifying the risk of early death for
individual patients, thus informing discussions between clini-
cians and patients as well as supporting the prognostic homo-
geneity of cohorts of patients enrolled to future clinical trials.
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Appendix
Instructions for Use of the Nomogram for 90-Day Mortality
First, risk points associated with each variable are obtained via vertical translation of the patient’s variable value (eg, BRAFMT)
to the scale labeled “Points” in the nomogram (ie, BRAF mutation contributes 20 points to 90-day mortality risk). Next, the points
associated with each variable value for the patient are totaled across the variables measured. This total is then located on the scale
“Total Points” and then vertically mapped to obtain the predicted probability of early mortality by 90 days (eg, 100 total points
corresponds to a predicted probability of approximately 27%).
Table A1. ARCAD Trials Used in Early Mortality Analyses
Trial Years Accrued Front-Line Treatment Arm(s) N
03-TTD-01 2002-2004 FUOX v CAPOX 340
AGITG (MAX) 2005-2007 Capecitabine v capecitabine plus bevacizumab v capecitabine
plus bevacizumab plus mitomycin
471
AIO22 2002-2004 FUFOX v CAPOX 469
AVF2107g 2000-2002 IFL v IFL plus bevacizumab 919
AVF2192g 2000-2002 5-FU v 5-FU plus bevacizumab 207
BICC-C 2003-2004 mIFL plus or minus bevacizumab v FOLFIRI plus or minus
bevacizumab v CapIRI
535
C97-3 1997-1999 FOLFOX6 v FOLFIRI 222
CAIRO 2003-2004 Capecitabine v CapIRI 820
CAIRO2 2005-2006 CAPOX plus bevacizumab v CAPOX plus bevacizumab plus
cetuximab
747
COIN 2005-2008 FOLFOX v FOLFOX plus cetuximab v intermittent FOLFOX 2,430
CRYSTAL 2004-2005 FOLFIRI plus cetuximab v FOLFIRI 1,212
FIRE II 2004-2006 XELOX plus cetuximab v CapIRI plus cetuximab 177
FIRE III 2007-2012 FOLFIRI plus bevacizumab v FOLFIRI plus cetuximab 589
FOCUS 2000-2003 5-FU v 5-FU plus oxaliplatin v 5-FU plus irinotecan 2,118
FOCUS II 2004-2006 5-FU v FOLFOX v capecitabine v CAPOX 456
GONO 2001-2005 FOLFOXIRI v FOLFIRI 244
HORG 99.30 2000-2004 FOLFOXIRI v FOLFIRI 283
HORIZON II 2006-2010 FOLFOX plus CAPOX plus cediranib v FOLFOX plus CAPOX 1,065
HORIZON III 2006-2009 FOLFOX plus cediranib v FOLFOX plus bevacizumab 1,584
MACRO 2006-2008 XELOX plus bevacizumab v bevacizumab 475
N016966 2004-2005 FOLFOX plus CAPOX plus bevacizumab v FOLFOX plus
CAPOX
2,017
N9741 1999-2001 IFL v FOLFOX v IROX 1,415
OPTIMOX 1 2000-2002 FOLFOX4 v FOLFOX7 621
OPTIMOX 2 2004-2006 mFOLFOX7 v mFOLFOX7 202
OPUS 2005-2006 FOLFOX4 v FOLFOX4 plus cetuximab 338
PACCE (C249) 2005-2006 Chemotherapy plus bevacizumab v chemotherapy plus
bevacizumab plus panitumumab
1,018
PRIME (C203) 2006-2008 FOLFOX v FOLFOX plus panitumumab 1,173
TRIBE 2008-2011 FOLFIRI plus bevacizumab v FOLFOXIRI plus bevacizumab 507
Total ARCAD 22,654
NOTE. Trials in italics had concurrent targeted v non-targeted randomization.
Abbreviations: AGITG, Australasian Gastro-Intestinal Trials Group; AIO, Arbeitsgemeinschaft Internistische Onkologie; ARCAD, Aide et Recherche en Cance´rologie
Digestive; AVF, anastomotic-vaginal ﬁstula; BICC, Breast Cancer in City and Country; CAIRO, Capecitabine, Irinotecan, and Oxaliplatin in Advanced Colorectal Cancer;
CapIRI, capecitabine and irinotecan; CAPOX, capecitabine plus oxaliplatin; COIN, Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in
Treating Patients With Metastatic Colorectal Cancer; CRYSTAL, Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer; FIRE II,
Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic
Colorectal Cancer; FIRE III, FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First-Line Treatment of Colorectal Cancer; FOCUS, Fluorouracil, Oxaliplatin,
and CPT11 Use and Sequencing; FOLFIRI, ﬂuorouracil, leucovorin, and irinotecan; FOLFOX, ﬂuorouracil, leucovorin, and oxaliplatin; FU, ﬂuorouracil; FUFOX, ﬂuorouracil
plus oxaliplatin; FUOX, continuous-infusion high-dose ﬂuorouracil plus oxaliplatin; GONO, Gruppo Oncologico Nord Ovest; HORG, Hellenic Oncology Research Group;
HORIZON II, Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy in PatientsWith UntreatedMetastatic Colorectal Cancer; HORIZON III, First-LineMetastatic
Colorectal Cancer Therapy in Combination With FOLFOX; IFL, irinotecan, leucovorin, and ﬂuorouracil; IROX, irinotecan and oxaliplatin; m, modiﬁed; MACRO, Main-
tenance in Colorectal Cancer; OPTIMOX 1, a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a
GERCOR study; OPTIMOX 2, Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study; OPUS, Oxaliplatin and
Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer; PACCE, Panitumumab Advanced Colorectal Cancer Evaluation; PRIME, Panitumumab Randomized
Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efﬁcacy; TRIBE, Combination Chemotherapy and Bevacizumab As First-Line
Therapy in Treating PatientsWithMetastatic Colorectal Cancer; TTD, Tratamiento de los Tumores Digestivos; XELOX, capecitabine plus oxaliplatin; 5-FU, ﬂuorouracil and
leucovorin.
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